The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1362
ISSUE1362
April 18, 2011
A New Testosterone Gel (Fortesta) for Hypogonadism
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
A New Testosterone Gel (Fortesta) for Hypogonadism
April 18, 2011 (Issue: 1362)
The FDA has approved Fortesta (Endo), a topical gel,
for testosterone replacement therapy in adult males
with hypogonadism. It is classified as a Schedule III
controlled substance. Table 1 lists some available
testosterone products, including 2...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.